Antenatal Corticosteroids in Early and Late Fetal Growth Restriction

Area of Science:

• Obstetrics and Gynecology
• Neonatology
• Pharmacology

Background:

• Antenatal corticosteroids (ACS) are standard for preterm birth to reduce neonatal morbidity and mortality.
• Concerns exist regarding neutral or detrimental effects of ACS in fetuses with fetal growth restriction (FGR).
• Fetal growth restriction may indicate heightened vulnerability to ACS in preterm infants.

Purpose of the Study:

• To evaluate the current scientific evidence on the effects of exogenous ACS in pregnancies complicated by FGR.
• To determine if gestational age influences the safety and efficacy of ACS in this specific obstetric population.

Main Methods:

• Systematic review of existing scientific literature.
• Analysis of studies examining ACS administration in pregnancies with FGR.
• Assessment of short- and long-term outcomes in exposed neonates.

Main Results:

• Current evidence regarding ACS effects in FGR pregnancies is inconclusive.
• Gestational age at administration (early vs. late preterm) is a critical factor requiring further assessment.
• Potential differential effects of ACS in FGR fetuses compared to non-FGR preterm infants.

Conclusions:

• The use of ACS as standard care in FGR pregnancies requires careful consideration due to inconclusive evidence.
• Further research is needed to clarify the risks and benefits of ACS based on gestational age in FGR.
• Individualized assessment is crucial for managing preterm birth in FGR pregnancies.